Nanoparticle vax cures Type 1 diabetes in mice

In a study co-funded by the Juvenile Diabetes Research Foundation, researchers at the University of Calgary were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. Using a sophisticated, nanotechnology-based “vaccine,” Dr. Pere Santamaria, Chair of the Julia McFarlane Diabetes Researcher Centre in UCalgary’s Faculty of Medicine and his team were able to specifically stop the autoimmune response that causes type 1 diabetes without damaging the immune cells that provide protection against infections. Dr. Santamaria notes that “if the paradigm on which this nanovaccine is based holds true in other chronic autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and others, nanovaccines might find general applicability in autoimmunity,"

- read this article for more

Suggested Articles

Takeda forged a feasibility pact to see whether it could pair a plasma-based therapy with Elektrofi's microparticle delivery tech.

RNA nanoparticles can squeeze into tumors and exit swiftly through the kidney, perfect for targeted delivery of cancer drugs, an OSU team says.

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.